| 8.26 -0.24 (-2.82%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.76 | 1-year : | 13.16 |
| Resists | First : | 10.07 | Second : | 11.27 |
| Pivot price | 9.03 |
|||
| Supports | First : | 8.14 | Second : | 6.77 |
| MAs | MA(5) : | 8.37 |
MA(20) : | 9.19 |
| MA(100) : | 7.28  |
MA(250) : | 6.45 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 9.1 |
D(3) : | 8.5 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 11.27 | Low : | 2.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SPRY ] has closed above bottom band by 13.4%. Bollinger Bands are 52.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.56 - 8.61 | 8.61 - 8.64 |
| Low: | 8.04 - 8.1 | 8.1 - 8.14 |
| Close: | 8.18 - 8.27 | 8.27 - 8.34 |
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Tue, 23 Apr 2024
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up to $8.21 - MarketBeat
Mon, 22 Apr 2024
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY): Are Analysts Optimistic? - Simply Wall St
Mon, 01 Apr 2024
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Fri, 22 Mar 2024
Ars Pharmaceuticals' Merger May Limit Use of Net Operating Losses, Impacting Future Financials - TipRanks.com - TipRanks
Fri, 15 Mar 2024
Ars Pharmaceuticals CEO sells over $900k in company stock - Investing.com
Mon, 26 Feb 2024
ARS Pharmaceuticals (SPRY) Reports neffy Met Endpoints in Phase 2 Trial - StreetInsider.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 3.722e+007 (%) |
| Held by Institutions | 27.4 (%) |
| Shares Short | 4,610 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.745e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -225 % |
| Return on Assets (ttm) | 66.6 % |
| Return on Equity (ttm) | -16.4 % |
| Qtrly Rev. Growth | 30000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 5.5e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|